Technical Analysis for SGMO - Sangamo BioSciences, Inc.

Grade Last Price % Change Price Change
C 2.02 3.33% 0.07
SGMO closed down 0.51 percent on Wednesday, November 20, 2024, on 83 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Wide Bands Range Expansion 3.33%
Gapped Up Strength 3.33%
Oversold Stochastic Weakness 3.33%
1,2,3 Pullback Bullish Bullish Swing Setup 2.81%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.81%
NR7 Range Contraction 2.81%
Stochastic Reached Oversold Weakness 2.81%
Inside Day Range Contraction 2.81%
Wide Bands Range Expansion 2.81%
Oversold Stochastic Weakness 2.81%

   Recent Intraday Alerts

Alert Time
Up 3% 17 minutes ago
Up 2% about 1 hour ago
Up 1% about 2 hours ago
60 Minute Opening Range Breakout about 2 hours ago
Down 3% about 2 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Sangamo BioSciences, Inc. Description

Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways; and ZFP transcription factors (ZFP TFs) proteins that could be used to turn genes on or off. The company's principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops SB-313xTZ that is in Phase I clinical trial for the treatment of glioblastoma. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, and huntington's disease; and proprietary programs in the areas of hemoglobinopathies and lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including certain immunodeficiency disorders. The company has collaboration, research, and license agreements with Shire AG; Sigma-Aldrich Corporation; Dow AgroSciences LLC; Genentech, Inc.; Open Monoclonal Technology, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Emerging Technologies Molecular Biology Blastoma Glioblastoma Immunodeficiency Hemoglobin Huntington's Disease Hemophilia Transcription Transcription Factors Cell Product Monogenic Hemophilia A Lysosomal Storage Disorder Transcription Factor Lysosomal Storage Disorders Monogenic Diseases Deficiency Syndrome Dow Agrosciences Hemoglobinopathies Hoffmann La Roche

Is SGMO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.179
52 Week Low 0.304
Average Volume 8,040,362
200-Day Moving Average 0.86
50-Day Moving Average 1.39
20-Day Moving Average 2.13
10-Day Moving Average 2.35
Average True Range 0.32
RSI (14) 51.46
ADX 39.0
+DI 24.17
-DI 17.31
Chandelier Exit (Long, 3 ATRs) 2.22
Chandelier Exit (Short, 3 ATRs) 2.11
Upper Bollinger Bands 2.93
Lower Bollinger Band 1.32
Percent B (%b) 0.39
BandWidth 75.93
MACD Line 0.22
MACD Signal Line 0.31
MACD Histogram -0.0945
Fundamentals Value
Market Cap 345.83 Million
Num Shares 177 Million
EPS -1.46
Price-to-Earnings (P/E) Ratio -1.34
Price-to-Sales 0.51
Price-to-Book 0.75
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.28
Resistance 3 (R3) 2.30 2.20 2.23
Resistance 2 (R2) 2.20 2.12 2.20 2.21
Resistance 1 (R1) 2.08 2.07 2.03 2.06 2.19
Pivot Point 1.98 1.98 1.96 1.98 1.98
Support 1 (S1) 1.86 1.90 1.81 1.84 1.71
Support 2 (S2) 1.76 1.85 1.76 1.69
Support 3 (S3) 1.64 1.76 1.68
Support 4 (S4) 1.62